Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials

• Published in: BMC cancer 2018-11, Vol.18 (1), p.1155-1155, Article 1155
• Main Authors: Marcath, Lauren A, Coe, Taylor D, Hoylman, Emily K, Redman, Bruce G, Hertz, Daniel L
• Format: Article
• Language: English
• Subjects: Cancer patients; Cancer therapies; Clinical trials; Clinical Trials as Topic; Demographic aspects; Drug Interactions; Drug therapy; Drugs; Enrollments; Female; Humans; Male; Medical Oncology; Neoplasms - drug therapy; Neoplasms - epidemiology; Nurses; Oncology; Oncology clinical trial drug interaction; Patient safety; Prevalence; Risk factors; Safety; Studies; Validity
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-5076-0

Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impact not only safety of the patient but also study drug outcomes and data validity. This makes it critical to adequately screen and manage DDIs. The study objective was to determine the prevalence of DDIs involving study medications in subjects enrolling in National Clinical Trials Network (NCTN) clinical trials at a single institution. DDIs were evaluated based on study protocol recommendations for concomitant medication use (i.e. exclude, avoid or use caution), screening via DDI tool, and pharmacist review. Subjects enrolled in NCTN trials of commercially available agents between January 2013 and August 2017 were included if a complete medication list was available. Complete medication lists were collected from the date of enrollment or the next available date then screened utilizing protocol guidance and the DDI screening tool, Lexicomp® Drug Interactions (Wolters Kluwer, Hudson, OH). Interactions were reviewed for clinical relevance: defined as a DDI that would require a medication change to ensure study agent safety and efficacy at enrollment. One hundred and twenty-eight subjects enrolled in 35 clinical trials were included. Protocol guidance detected 15 unique DDI pairs that should be avoided or used with caution in 10.2% (13/128) of subjects. The majority of these subjects did not have a clinically relevant DDI (69.2%, 9/13) based on pharmacist review. Lexicomp® detected moderate to major DDIs in 24.2% (31/128) of subjects, with 9.4% (12/128) having a clinically relevant DDI. This study confirms a high prevalence of DDIs present in subjects enrolling in oncology clinical trials. Further efforts should be made to improve methods to detect and manage DDIs in patients enrolling on clinical trials to ensure patient safety and trial data validity.